系统性硬化症合并肺高压且楔压升高患者的临床特征与生存:PHAROS队列观察
基于PHAROS前瞻性观察队列,纳入右心导管平均肺动脉压≥25 mmHg且肺动脉楔压>15 mmHg的59例系统性硬化症相关肺高压患者,按舒张压差分为混合性肺高压21例(36%)与毛细血管后肺高压38例(64%)。两组基线特征、生存及肺高压相关住院均无差异;基线6分钟步行距离降低是唯一与死亡独立相关的因素。混合性肺高压组随访中启用肺高压特异性药物者更多(86% vs 50%,P=0.01)。
要点
- 平均肺动脉压≥25且楔压>15的系统性硬化症肺高压患者中,混合性肺高压占36%。
- 混合性与毛细血管后肺高压两组生存和肺高压相关住院无差异。
- 基线6分钟步行距离每降低25米,死亡风险比1.33(95%CI 1.11-1.59,P=0.002)。
核心结论
- 系统性硬化症合并毛细血管后肺高压与混合性前后毛细血管肺高压的结局相似。
- 基线6分钟步行距离可预测楔压升高的系统性硬化症肺高压患者死亡风险。
- 混合性肺高压组更多启用肺高压特异性药物,该亚组治疗的临床获益尚待进一步探索。
研究设计与样本
- PHAROS注册研究为系统性硬化症相关肺高压患者的前瞻性观察队列。
- 纳入右心导管平均肺动脉压≥25且肺动脉楔压>15的患者共59例,按舒张压差分层。
- 混合性肺高压21例(36%),毛细血管后肺高压38例(64%)。
- 采用Kaplan-Meier分析比较生存与肺高压相关住院,Cox回归分析基线因素与死亡的关系。
主要发现
- 两组基线特征无显著差异。
- 两组生存与肺高压相关住院无差异。
- 唯一与死亡独立相关的基线因素为较低的6分钟步行距离(每降低25米,HR 1.33,95%CI 1.11-1.59,P=0.002)。
- 随访期间混合性肺高压组启用肺高压特异性药物者显著多于毛细血管后组(86% vs 50%,P=0.01)。
关键数值与推荐
- 右心导管入组标准:平均肺动脉压≥25、肺动脉楔压>15。
- 分层依据:舒张压差,分为混合性肺高压与毛细血管后肺高压。
- 死亡风险:6分钟步行距离每降低25米,HR 1.33(95%CI 1.11-1.59,P=0.002)。
- 肺高压特异性药物启用比例:86% vs 50%,P=0.01。
临床怎么用
- 对系统性硬化症合并肺高压且楔压升高者,可依据舒张压差区分混合性与毛细血管后肺高压。
- 基线6分钟步行距离可用于该人群死亡风险分层。
- 混合性肺高压患者更多接受肺高压特异性药物,但需进一步研究其临床获益。
局限性
- 样本量较小,共59例。
- 为前瞻性观察队列,非随机对照研究。
- 混合性肺高压亚组特异性治疗的临床获益尚需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Systemic sclerosis (SSc) is a complex autoimmune disease commonly associated with pulmonary hypertension (PH). When associated with elevated pulmonary artery wedge pressure (PAWP), pulmonary artery pressure (PAP) is either in-proportion (post-capillary PH) or higher than expected (combined PH) relative to the increased PAWP. METHODS: Patients from the PHAROS registry (a prospective observational cohort of SSc-PH patients) who had mean PAP ≥ 25 and PAWP > 15 on right heart catheterization were stratified based on diastolic pressure gradient (DPG). Kaplan-Meier analysis was performed to compare survival and PH-related hospitalization. Baseline factors were compared between patients dying and those who survived using Cox regression analysis. RESULTS: A total of 59 patients were included, of whom 21 (36%) patients were classified as combined PH and 38 (64%) had post-capillary PH. No baseline characteristics were significantly different between the two groups. There were no differences in survival or PH-related hospitalization between the groups. The only baseline factor independently associated with death was lower 6-min walk distance (6MWD) (hazard ratio (HR): 1.33 per 25 m decrease, 95% CI: 1.11-1.59, P = 0.002). PH-specific medications were started during follow-up in significantly more patients in the combined PH group compared with the post-capillary group (86% vs 50%, P = 0.01). CONCLUSION: Outcomes were similar between SSc patients with post-capillary PH and combined pre- and post-capillary PH. 6MWD at baseline can predict risk for death in SSc patients with PH and an elevated PAWP. More patients with combined PH were started on PH-specific medications, and the clinical benefit of treating this subgroup specifically in SSc patients needs further exploration.
引用
- Lammi MR, Saketkoo LA, Gordon JK, et al. Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort. Respirology. 2017. PMID: 28500695. doi:10.1111/resp.13067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。